Connecting private and
public R&D

Resource mobilisation for multilaterals, nonprofits, and companies endeavouring to improve global health.

Navigating
the global health landscape

As cross-sector collaborations increasingly drive equitable and resilient global health, Global Health RX offers end-to-end strategies to bridge sectors and reach investment, peer, policy and public audiences.

Resource Mobilisation
Stakeholder Engagement
Communications and Publications

Learn More

Years Experience

Led by Barbara Nasto, Global Health RX draws on nearly two decades of collaborating with diverse research communities to cultivate partnerships and investment across the global health and biopharmaceutical ecosystem.

Resource mobilisation

Global Health RX excels in translating clinical, financial and other complex evidence and data into proposals, reports, and media for engaging public funders, private investors and stakeholder agencies and partners.

Strategy and
Engagement

Global Health RX provides strategic communications and publications from the highly technical to the broadly accessible.

Services

Global Health RX translates complex science and evidence into funding, investment, policy and communications.

Resource mobilisation

Blended financing or individual project management, no project is too great or too small.

grant writing
investment proposal development
fundraising strategy
business plan development
advocacy campaigns

Strategic publications and communications

Writing, editing and multimedia storytelling are agile tools adapted to achieve your programme and project goals.

multimedia storytelling
- custom illustration
- photo
- video
- podcast
journal manuscripts and analytical reports
- impact
- annual
- advocacy
thought-leadership
- speech writing
- blogs and op-eds

Stakeholder Engagement

Building, managing, and optimising collaborative relationships between businesses, public sector organisations, and mission driven non-profits requires thorough research and ways to communicate it.

landscape scanning
due diligence
governance strategy
policy analysis
infographics
newsletters
social media strategy

Select Publications

With the goal of enhancing collaboration between the public and private R&D sectors, Barbara publishes analysis on topics related to drug and vaccine development driven by both companies and nonprofit organisations. Academically, Barbara is monitoring the emergence of new public private partnership models and assessing the resilience of existing cross-sector clinical R&D programmes to changes in development funding and health policy since 2015. Sub-analysis and observations associated with this investigation are featured in the site's blog.

Hope for control of centuries old epidemic

The pipeline of therapeutics and vaccines to treat or prevent tuberculosis is postured to bring one of humanity’s oldest and deadliest infectious diseases under control.

Nat Med. 2026 May;32(5):1560-1562 doi: 10.1038/d41591-026-00019-1.

The patient is now in the room

Patient-driven therapeutic development, once relegated to the realm of rare diseases is moving into the mainstream.

Nat Med. 2026 Apr;32(4):1166-1169. doi: 10.1038/s41591-026-04335-4.

First orexin agonists address root cause of narcolepsy

A new class of agents is poised to transform treatment for people with narcolepsy. Credited with discovering the gene for narcolepsy and making the link to the absence of orexin in narcolepsy patients, Emmanuel Mignot, a practicing psychiatrist and Professor of Sleep Medicine at Stanford University, cultivated the research base fostering multiple clinical discovery platforms developing OX2R agonists.

Non-profits wade in where for-profit life science investment
fears to tread

For decades, and in the exceptional instance of the Institut Pasteur for over a century, non-profit organisations continuously advance affordable and accessible pipelines of vaccines, medicines and diagnostics in the biopharmaceutical ecosystem.

Nat Biotechnol 2025 Aug;43(8):1221-1226. doi: 10.1038/s41587-025-02752-3.